Indicated for: cancer
Route of administration: injectable
Substance: carmustine (antineoplastic agent)
ATC: L01AD01 (Antineoplastic and immunomodulating agents | Alkylating agents | Nitrosoureas)
This medicine may affect fertility.
Dose adjustment may be needed in liver disease.
Handle with special care.
Effective contraception is required during treatment.
Do not use this medicine while breastfeeding.
Do not use this medicine during pregnancy.
This medicine may affect the liver.
This medicine may have important interactions with other medicines.
This medicine may lower blood cell counts.
This medicine is subject to additional monitoring.
Periodic laboratory tests may be required during treatment.
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Carmustine is a chemotherapy medication used to treat certain types of cancer, including lymphomas, multiple myeloma, and brain tumors. It belongs to the class of alkylating agents and works by interfering with the DNA of cancer cells, inhibiting their division and growth.
Carmustine is administered intravenously or as implants in the case of brain tumors. Treatment is usually given in cycles, and the dosage is adjusted based on the patient's weight, overall health, and the type of cancer being treated.
Patients need to be closely monitored during treatment to detect potential side effects, such as pulmonary toxicity, decreased blood cell counts, or liver function impairment. It is important to strictly follow the doctor's instructions.
Common side effects include nausea, vomiting, fatigue, and an increased risk of infections. In rare cases, more severe complications such as pulmonary fibrosis or liver failure may occur. Patients should inform their doctor of any unusual symptoms.